Brief: Viking Therapeutics Presents Data From Its 13-Week Phase 2 Venture-Oral Dosing Trial
12/05/2026 12:07
May 12 (Reuters) - Viking Therapeutics Inc VKTX.O: VIKING THERAPEUTICS PRESENTS DATA FROM ITS 13-WEEK PHASE 2 VENTURE-ORAL DOSING TRIAL OF VK2735 AT EUROPEAN CONGRESS ON OBESITY (ECO) 2026 Source text: ID:nPnc6PHdba Further company coverage: VKTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Viking Therapeutics
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry